The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-(4-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)benzylideneamino)-N'-(5-methylisoxazol-3-yl)benzenesulfonohydrazide ID: ALA4878420
PubChem CID: 164628060
Max Phase: Preclinical
Molecular Formula: C23H23N7O6S
Molecular Weight: 525.55
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: Cc1cc(NNS(=O)(=O)c2ccc(/N=C\c3ccc(OCCn4c([N+](=O)[O-])cnc4C)cc3)cc2)no1
Standard InChI: InChI=1S/C23H23N7O6S/c1-16-13-22(27-36-16)26-28-37(33,34)21-9-5-19(6-10-21)25-14-18-3-7-20(8-4-18)35-12-11-29-17(2)24-15-23(29)30(31)32/h3-10,13-15,28H,11-12H2,1-2H3,(H,26,27)/b25-14-
Standard InChI Key: HSGGOYNQIHGRMC-QFEZKATASA-N
Molfile:
RDKit 2D
37 40 0 0 0 0 0 0 0 0999 V2000
18.9068 -17.0950 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
19.7240 -17.0950 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
19.3154 -16.3873 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
15.4895 -17.0949 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
16.1525 -16.6170 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.8981 -15.8362 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.0809 -15.8362 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.8265 -16.6170 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.0497 -16.8707 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9342 -16.8704 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.5423 -16.3245 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
17.1029 -17.6699 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
15.4895 -17.9121 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.1972 -18.3207 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.1972 -19.1379 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
16.9049 -19.5465 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9024 -20.3648 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.6092 -20.7733 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.3179 -20.3647 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.3153 -19.5433 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.6079 -19.1384 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.0262 -20.7723 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.7334 -20.3628 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
19.7323 -19.5456 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.4390 -19.1395 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.4382 -18.3231 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.7295 -17.9146 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.0199 -18.3285 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.0242 -19.1436 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.4339 -16.6869 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
20.4354 -15.8697 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
21.1439 -15.4625 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.8905 -15.7943 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
22.4385 -15.1881 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
22.0312 -14.4795 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.2316 -14.6480 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.3649 -13.7336 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 2 0
7 8 2 0
5 6 2 0
4 5 1 0
6 7 1 0
8 4 1 0
8 9 1 0
10 11 2 0
10 12 1 0
5 10 1 0
4 13 1 0
13 14 1 0
14 15 1 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 16 1 0
19 22 1 0
22 23 2 0
23 24 1 0
24 25 2 0
25 26 1 0
26 27 2 0
27 28 1 0
28 29 2 0
29 24 1 0
27 2 1 0
2 30 1 0
30 31 1 0
31 32 1 0
32 33 2 0
33 34 1 0
34 35 1 0
35 36 2 0
36 32 1 0
35 37 1 0
M CHG 2 10 1 12 -1
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 525.55Molecular Weight (Monoisotopic): 525.1431AlogP: 3.53#Rotatable Bonds: 11Polar Surface Area: 166.78Molecular Species: NEUTRALHBA: 11HBD: 2#RO5 Violations: 2HBA (Lipinski): 13HBD (Lipinski): 2#RO5 Violations (Lipinski): 2CX Acidic pKa: 9.92CX Basic pKa: 3.05CX LogP: 3.62CX LogD: 3.62Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.17Np Likeness Score: -2.14
References 1. Patel OPS, Jesumoroti OJ, Legoabe LJ, Beteck RM.. (2021) Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective., 210 [PMID:33234343 ] [10.1016/j.ejmech.2020.112994 ]